Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention

被引：79
作者：
Garcia-Vidal, C. [1 ,2 ]
Rodriguez-Fernandez, S. [2 ]
Teijon, S. [2 ]
Esteve, M. [3 ]
Rodriguez-Carballeira, M. [2 ]
Lacasa, J. M. [2 ]
Salvador, G. [4 ]
Garau, J. [2 ]
机构：
[1] Hosp Univ Bellvitge, Infect Dis Serv, Barcelona 08907, Spain
[2] Univ Barcelona, Hosp Mutua Terrassa, Serv Internal Med, Barcelona, Spain
[3] Univ Barcelona, Hosp Mutua Terrassa, Serv Gastroenterol, Barcelona, Spain
[4] Univ Barcelona, Hosp Mutua Terrassa, Serv Rheumatol, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2009年 / 28卷 / 04期
关键词：
TUBERCULIN SKIN-TEST; NECROSIS-FACTOR ANTAGONISTS; FACTOR-ALPHA ANTAGONISTS; GAMMA RELEASE ASSAYS; RHEUMATOID-ARTHRITIS; LATENT TUBERCULOSIS; HEPATITIS-B; THERAPY; METHOTREXATE; REACTIVATION;
D O I：
10.1007/s10096-008-0628-x
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
We sought to determine factors associated with opportunistic infections (OI) in infliximab-treated patients. A retrospective study cohort (1999-2004) was examined. Nine OI were diagnosed in 94 infliximab-treated patients: tuberculosis (four), visceral leishmaniasis (one), pyogenic muscular abscess (one Salmonella spp. and one Streptococcus pneumoniae), and two viral infections (hepatitis B virus [HBV] and zoster ophthalmicus). The risk for OI was significantly higher in the first year of treatment (odds ratio [OR] 8; 95% confidence interval [CI] 2-50). Previous treatment with more than two immunosuppressive drugs was the only factor related to OI (OR 8.686; 95% CI 1.889-39.943). We identified the subset of patients treated with infliximab who had a higher risk for OI. The screening of latent infections is key to diminishing the incidence of these infections.
引用
收藏
页码：331 / 337
页数：7
相关论文
共 50 条
  • [1] Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide
    Yoo, Han-Gyul
    Yu, Hea Min
    Jun, Jeon Byung
    Jeon, Hyun-Soon
    Yoo, Wan-Hee
    MODERN RHEUMATOLOGY, 2013, 23 (04) : 709 - 715
  • [2] Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
    Buonomo, Antonio Riccardo
    Zappulo, Emanuela
    Viceconte, Giulio
    Scotto, Riccardo
    Borgia, Guglielmo
    Gentile, Ivan
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (07) : 709 - 717
  • [3] Opportunistic Infections in Biological Therapy, Risk and Prevention
    Bryant, Paul A.
    Baddley, John W.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2017, 43 (01) : 27 - +
  • [4] Unusual presentation of tuberculosis in an infliximab-treated patient - which is the correct TB screening before starting a biologic?
    Gori, Alessia
    Fabroni, Caterina
    Prignano, Francesca
    Lotti, Torello
    DERMATOLOGIC THERAPY, 2010, 23 : S1 - S3
  • [5] A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease
    Naganuma, Makoto
    Kunisaki, Reiko
    Yoshimura, Naoki
    Takeuchi, Yoshiaki
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY, 2013, 48 (05) : 595 - 600
  • [6] Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients
    Swaminath, A.
    Ullman, T.
    Rosen, M.
    Mayer, L.
    Lichtiger, S.
    Abreu, M. T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (03) : 273 - 278
  • [7] Risk of infections in rheumatoid arthritis patients treated with tocilizumab
    Lang, Veronika R.
    Englbrecht, Matthias
    Rech, Juergen
    Nuesslein, Hubert
    Manger, Karin
    Schuch, Florian
    Tony, Hans-Peter
    Fleck, Martin
    Manger, Bernhard
    Schett, Georg
    Zwerina, Jochen
    RHEUMATOLOGY, 2012, 51 (05) : 852 - 857
  • [8] Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients
    Dubinsky, Marla C.
    Phan, Becky L.
    Singh, Namita
    Rabizadeh, Shervin
    Mould, Diane R.
    AAPS JOURNAL, 2017, 19 (01): : 215 - 222
  • [9] Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab
    Osterman, Mark T.
    Sandborn, William J.
    Colombel, Jean-Frederic
    Peyrin-Biroulet, Laurent
    Robinson, Anne M.
    Zhou, Qian
    Lewis, James D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (12) : 1806 - 1815
  • [10] A fulminant colitis index greater or equal to 8 is not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks
    Baudet, A.
    Colombel, J. -F.
    Cortot, A.
    Dupas, J. -L.
    Brazier, F.
    Savoye, G.
    Lerebours, E.
    Justum, A. -M.
    Reimund, J. -M.
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2010, 34 (11): : 612 - 617
12345